CJC-1295 and Mod GRF (1-29): Research Overview

CJC-1295 is one of the most extensively characterized synthetic analogs of growth-hormone-releasing hormone (GHRH) in the peptide research literature. It exists in two closely related forms that are frequently confused: a version bearing a Drug Affinity Complex (DAC) and a version without it, the latter commonly designated Modified GRF (1-29) or Mod GRF (1-29). The distinction between these two molecules is not cosmetic. It governs their circulating stability, their pharmacokinetic profile in preclinical models, and the experimental questions each is best suited to address. This overview examines the molecular identity of CJC-1295, the GHRH-receptor pathway it engages, the DAC versus no-DAC distinction, and why researchers so often study it alongside ghrelin-receptor peptides.

Molecular Identity and Structural Basis

CJC-1295 is derived from the N-terminal region of native GHRH. Endogenous GHRH is a 44-amino-acid peptide, but its receptor-activating potency is concentrated in the first 29 residues, GHRH(1-29). This fragment forms the structural scaffold for both CJC-1295 variants. The molecule incorporates a small number of amino-acid substitutions at positions known in the literature to be vulnerable to enzymatic cleavage — most notably the site targeted by dipeptidyl peptidase-IV (DPP-IV). These substitutions are the defining feature of the "Modified GRF (1-29)" designation and were engineered to slow the rapid proteolytic degradation that limits native GHRH.

The DAC-bearing form adds a further chemical element: a maleimidopropionyl-lysine moiety appended to the peptide. This is the "Drug Affinity Complex." In a biological milieu, this reactive group forms a covalent bond with a free thiol on circulating serum albumin — the cysteine-34 residue described in the pharmacokinetic literature. The result is a peptide-albumin conjugate that resists renal filtration and enzymatic clearance.

The GHRH-Receptor Pathway

Both variants act as agonists at the growth-hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. In the canonical signaling cascade documented in preclinical models, agonist binding activates a stimulatory G-protein, which in turn activates adenylate cyclase. The resulting rise in intracellular cyclic AMP (cAMP) engages protein kinase A and promotes both the synthesis and the pulsatile release of growth hormone (GH) from somatotroph stores.

Because CJC-1295 engages the same receptor as native GHRH, in vitro and animal-model studies have used it as a tool to probe GHRH-receptor pharmacology, somatotroph responsiveness, and the downstream cAMP-dependent machinery that governs GH secretion. A researcher comparing GHRH-analog compounds may find the mechanistic context in our companion guide on growth hormone secretagogues useful for situating CJC-1295 within the broader secretagogue landscape.

DAC vs No-DAC: The Half-Life Distinction

The most consequential difference between the two forms is their circulating persistence, a topic the pharmacokinetic literature treats in detail.

Mod GRF (1-29), the no-DAC form, is a short-acting molecule. Even with the DPP-IV-resistant substitutions, its residence in circulation is measured in minutes rather than hours in the models studied. This brevity produces a sharp, transient stimulus — a discrete pulse of receptor activation that then decays. For experimental designs that aim to mimic the naturally episodic, pulsatile character of GHRH signaling, this short profile is often the point.

The DAC form behaves entirely differently. By tethering itself covalently to albumin, it converts the abundant plasma protein into a slow-release depot, and its measured half-life in the literature extends to a timescale of days rather than minutes. This produces sustained, tonic elevation of receptor exposure rather than a discrete pulse.

The DAC modification does not change which receptor is engaged — it changes for how long. The pathway is identical; the temporal signature is not.

This divergence makes the two variants complementary research tools. The short-acting CJC-1295 NO DAC (Mod GRF 1-29) is studied where a transient, pulse-like stimulus is desired, while the long-acting CJC-1295 DAC (5mg) is used in protocols examining sustained GHRH-receptor engagement over extended intervals.

Why It Is Combined With Ghrelin-Receptor Peptides

A recurring theme in the secretagogue literature is the pairing of GHRH analogs such as CJC-1295 with a second, mechanistically distinct class: the ghrelin-receptor agonists, which include the growth-hormone-releasing peptides (GHRPs) such as Ipamorelin. The rationale is rooted in dual-pathway physiology.

GH secretion is governed by two convergent regulatory inputs. GHRH acts through the GHRHR and the cAMP-dependent pathway described above. Ghrelin and the GHRPs act through a separate receptor — the growth hormone secretagogue receptor GHS-R1a — which signals through a distinct, largely calcium-dependent cascade. Because these two arms operate through different receptors and different second-messenger systems, preclinical studies have examined whether concurrent stimulation produces GH release exceeding the sum of either input alone.

• Complementary receptors: GHRHR (cAMP-mediated) versus GHS-R1a (calcium-mediated), allowing independent engagement of two regulatory pathways.
• Convergent output: both pathways ultimately modulate somatotroph GH release, making them a natural pairing for co-stimulation experiments.
• Amplitude and gating: the literature often frames the GHRP component as gating or initiating a release event while the GHRH analog amplifies its magnitude.

This mechanistic logic is why fixed-ratio research preparations such as the CJC-1295 & Ipamorelin Blend (10mg) are common study articles. For a closer look at the ghrelin-receptor side of this pairing, our Ipamorelin research guide examines that selective GHRP in detail.

Analytical Characterization and Research Context

As with any peptide research material, identity and purity are central concerns. Analytical characterization of CJC-1295 preparations in the literature typically relies on reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and on mass spectrometry to confirm molecular mass and, in the DAC form, the presence of the appended complex. Distinguishing the DAC and no-DAC variants analytically is important precisely because their pharmacokinetic behavior differs so markedly — a point of frequent methodological attention in the research record.

This article is provided for educational and informational purposes only. CJC-1295, Mod GRF (1-29), and all related compounds referenced here are intended strictly for laboratory and in-vitro research use. They are not drugs, dietary supplements, or medical products, and nothing above should be interpreted as describing human or veterinary use, treatment, or outcomes. All materials supplied by Core Peptides are for research applications conducted by qualified professionals only.